Cytomx Thera (CTMX) Stock Price, Quote & News

Company Profile

CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators,...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 515 3185

Fax: 650 351 0353

Website: www.cytomx.com

Address:

151 Oyster Point Boulevard, Suite 400, South San Francisco, United States

Dubbyy Aug. 4 at 11:19 AM

$CTMX Check out this article from TipRanks | CTMX Earnings Report this Week: Is It a Buy, Ahead of Earnings? | https://tipranks.onelink.me/WJho/kxnhyjxu

0 · Reply

Mavi93 Aug. 4 at 10:56 AM

$CTMX Interesting to see what has happened at CytomX over the past few months. Charles Fuchs, Rachel Humphrey and Alejandra Carvajal have all joined the leadership team. People with this level of experience usually do not join a company unless they see real potential. Whether it is upcoming clinical data, partnerships or other strategic opportunities, it feels like CytomX is preparing for its next stage. To me, that is a very positive sign.

0 · Reply

Bionco Aug. 3 at 5:10 PM

$CTMX BOA just filed 13G, added more in the past Q with 7% ownership now!

1 · Reply

HoldenMeown Aug. 3 at 2:16 PM

$CTMX Just bought more

0 · Reply

Goyimlivesmatter Aug. 3 at 1:52 PM

$CTMX slow bleed

2 · Reply

Dubbyy Aug. 3 at 1:33 PM

$CTMX Check out this article from TipRanks | CytomX Therapeutics appoints Alejandra Carvajal as chief legal officer | https://tipranks.onelink.me/WJho/9kc063qv

0 · Reply

Bionco Aug. 3 at 12:04 AM

$CTMX I hope they will separately release the data from the escalation/expansion cohorts and the dose-optimization cohorts to boost the stock. Combined with the CX801 data, that would give us three catalysts later this year.......

1 · Reply

Scumbag20 Aug. 2 at 8:25 PM

$CTMX https://www.facebook.com/share/v/19LrcKxTSB/

1 · Reply

Bionco Aug. 2 at 1:40 PM

$CTMX For the upcoming earnings, I’m not really expecting any big bombshells. The big thing I’m watching for is whether they give us a safety update from the dose optimization cohort. They finished enrolling patients for the dose escalation and expansion cohorts back in August 2025, so by September this year, the mOS data should be pretty mature. The real question is when are they going to share it? As for the dose optimization cohort, that started enrolling in August 2025 too. The first 20 patients were in by mid January, and another 20 joined in early April. I’m guessing the data cutoff for PFS could happen no later than September. If that timing holds, we might see PFS data pop up during the Q3 earnings call in early November, Or will the company attend ESMO conference this year? It will take place in late October. CTMX has been getting bitterly hammered by shorts since March 16th, with >60% down from the recent high. But honestly? Patient longs are gonna get theri days!

2 · Reply

Gator5326 Aug. 2 at 12:43 PM

$CTMX Interesting read https://www.linkedin.com/posts/in-this-issue-of-harvard-medicine-insights-ugcPost-7486155976707031041--X5-/?utm_source=social_share_send&utm_medium=ios_app&rcm=ACoAADjpvv4BUYqMVzhFvSrmneh4imt5DKT-E-s&utm_campaign=copy_link

0 · Reply

CytomX Therapeutics appoints Alejandra Carvajal as chief legal officer

Aug 3, 2026, 8:00 AM EDT - 1 day ago

CytomX Therapeutics Appoints Alejandra Carvajal as Chief Legal Officer

Jul 30, 2026, 8:00 AM EDT - 5 days ago

CytomX Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026

Jul 27, 2026, 8:00 AM EDT - 8 days ago

CytomX Therapeutics Announces Appointment of Charles Fuchs, M.D., M.P.H., to the Board of Directors

Jun 10, 2026, 9:20 AM EDT - 7 weeks ago

CytomX Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 4, 2026, 3:10 PM EDT - 2 months ago

CytomX Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

2026-06-03T13:28:50.000Z - 2 months ago

CytomX Therapeutics expands licensing agreement with Regeneron

REGN

Jun 3, 2026, 8:00 AM EDT - 2 months ago

CytomX Announces Expansion of Strategic Research Collaboration with Regeneron in the Field of Conditional Bispecific Therapeutics for the Treatment of Cancer

May 21, 2026, 8:00 AM EDT - 2 months ago

CytomX Therapeutics to Present at Upcoming June Investor Conferences

2026-05-19T10:13:05.000Z - 2 months ago

CytomX Therapeutics initiated with an Outperform at Wolfe Research

May 18, 2026, 8:00 AM EDT - 2 months ago

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

2026-05-11T10:24:04.000Z - 3 months ago

CytomX Therapeutics price target lowered to $11 from $17 at H.C. Wainwright

2026-05-07T22:15:03.000Z - 3 months ago

CytomX Therapeutics reports Q1 EPS (10c), consensus (11c)

May 7, 2026, 5:00 PM EDT - 3 months ago

CytomX Therapeutics Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

CytomX Therapeutics Quarterly report: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

CytomX Therapeutics Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 3 months ago

CytomX Therapeutics Slides: Q1 2026

May 7, 2026, 4:15 PM EDT - 3 months ago

CytomX Therapeutics Announces Q1 2026 Financial Results and Provides Business Update

Apr 30, 2026, 8:00 AM EDT - 3 months ago

CytomX Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026

Apr 30, 2026, 8:00 AM EDT - 3 months ago

CytomX Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 3 months ago

CytomX Therapeutics Proxy statement: Proxy filing

Apr 20, 2026, 8:00 AM EDT - 3 months ago

CytomX Therapeutics Proxy statement: Proxy filing

2026-04-13T14:25:10.000Z - 4 months ago

CytomX Therapeutics participates in a conference call with JPMorgan

2026-03-23T10:55:06.000Z - 4 months ago

CytomX Therapeutics price target raised to $12 from $10 at Piper Sandler

2026-03-19T09:25:41.000Z - 4 months ago

CytomX Therapeutics price target raised to $16 from $10 at Barclays

2026-03-18T14:25:35.000Z - 4 months ago

CytomX Therapeutics price target raised to $16 from $8 at Jefferies

2026-03-18T11:05:22.000Z - 4 months ago

CytomX Therapeutics price target raised to $15 from $10 at Guggenheim

2026-03-18T10:12:07.000Z - 4 months ago

CytomX Therapeutics 45.9M share Secondary priced at $5.30

Mar 17, 2026, 10:46 PM EDT - 4 months ago

CytomX Therapeutics Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

2026-03-17T11:56:10.000Z - 5 months ago

CytomX Therapeutics price target raised to $11 from $6 at Wedbush

2026-03-16T20:10:52.000Z - 5 months ago

CytomX Therapeutics announces $250M common stock offering

2026-03-16T20:05:42.000Z - 5 months ago

CytomX Therapeutics files automatic mixed securities shelf

Mar 16, 2026, 4:04 PM EDT - 5 months ago